155 related articles for article (PubMed ID: 14761814)
1. Active surveillance: towards a new paradigm in the management of early prostate cancer.
Parker C
Lancet Oncol; 2004 Feb; 5(2):101-6. PubMed ID: 14761814
[TBL] [Abstract][Full Text] [Related]
2. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
3. Role of the pathologist in active surveillance for prostate cancer.
Mazzucchelli R; Galosi AB; Santoni M; Lopez-Beltran A; Scarpelli M; Cheng L; Montironi R
Anal Quant Cytopathol Histpathol; 2015 Feb; 37(1):65-8. PubMed ID: 26072636
[TBL] [Abstract][Full Text] [Related]
4. Active surveillance of early prostate cancer: rationale, initial results and future developments.
Parker C
Prostate Cancer Prostatic Dis; 2004; 7(3):184-7. PubMed ID: 15224088
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
van den Bergh RC; Roemeling S; Roobol MJ; Wolters T; Schröder FH; Bangma CH
Eur Urol; 2008 Sep; 54(3):505-16. PubMed ID: 18585845
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
[TBL] [Abstract][Full Text] [Related]
7. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
9. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
10. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
11. Active surveillance for prostate cancer: progress and promise.
Cooperberg MR; Carroll PR; Klotz L
J Clin Oncol; 2011 Sep; 29(27):3669-76. PubMed ID: 21825257
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
Klotz L
Eur Urol; 2005 Jan; 47(1):16-21. PubMed ID: 15582244
[TBL] [Abstract][Full Text] [Related]
13. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Krakowsky Y; Loblaw A; Klotz L
J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
[TBL] [Abstract][Full Text] [Related]
15. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
[TBL] [Abstract][Full Text] [Related]
16. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.
Bul M; Zhu X; Valdagni R; Pickles T; Kakehi Y; Rannikko A; Bjartell A; van der Schoot DK; Cornel EB; Conti GN; Boevé ER; Staerman F; Vis-Maters JJ; Vergunst H; Jaspars JJ; Strölin P; van Muilekom E; Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2013 Apr; 63(4):597-603. PubMed ID: 23159452
[TBL] [Abstract][Full Text] [Related]
17. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression.
Dall'Era MA; Konety BR
Nat Clin Pract Urol; 2008 May; 5(5):277-83. PubMed ID: 18285752
[TBL] [Abstract][Full Text] [Related]
18. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
19. PSA relapse prostate cancer: the importance of tailored therapy.
Aranha O; Vaishampayan U
Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
[TBL] [Abstract][Full Text] [Related]
20. Active surveillance for prostate cancer: for whom?
Klotz L
J Clin Oncol; 2005 Nov; 23(32):8165-9. PubMed ID: 16278468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]